BioAdvance Capital
BioAdvance Capital is an evergreen fund focused on investing in early-stage life-science companies that have the potential to enhance human well-being and quality of life. With a long-term investment perspective, BioAdvance primarily targets companies in the Mid-Atlantic region. Their portfolio companies have collectively attracted over $4.2 billion in external capital to support their growth.
BioAdvance Capital
Portfolio
Holds a game-changing platform exploiting protein-conformation dynamics to discover next generation GPCR drugs devoid of on-target side effects.
#Biotechnology
Develops and commercializes sensor-based technologies and platform to improve medication adherence and care coordination in respiratory care.
#Healthcare Technology
Offers an AI-assisted virtual alternative to rehabilitative care for patients with cardiac and pulmonary-related diagnoses.
#Healthcare Technology
RNAimolecule to treat macular degeneration. Merged into Opko Health, Inc. in 2007.
#Biotechnology
Providing the allogeneic human Trophoblast Stem Cell (TSC) platform as the ideal starting cell source for cell and gene therapy.
#Biotechnology
Therapeutics and vaccines (CDX-110) against novel, proprietary cancer targets. Acquired by Celldex Therapeutics in 2005.
#Biotechnology